<DOC>
	<DOC>NCT02792335</DOC>
	<brief_summary>To describe the rate of discontinuation among Non-Valvular Atrial Fibrillation (NVAF) patients who were on warfarin and have switched to the Novel oral anticoagulants(NOACs).</brief_summary>
	<brief_title>Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Individuals with NVAF who were on warfarin and have switched to the NOACs (dabigatran, rivaroxaban and apixaban) within the study period January 01, 2013 through March 31, 2014 Individuals â‰¥18 years old on the index date At least 1 year of baseline period with history of continuous warfarin use in the baseline period for at least 3 months immediately before the index date At least 1 diagnosis of AF in the 12 months prior to index date Continuous eligibility with medical and pharmacy benefits for at least 12 months before the index date through 1 month after the index date Individuals with a diagnosis of valvular heart disease or cardiac surgery during the 12 months prior to index date</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>